construction and functional characterization of a fully human anti-mesothelin chimeric antigen receptor (car) expressing t cell

Chimeric antigen receptor (car) t cell therapy is considered as an encouraging approach for the treatment of hematological malignancies. however, its efficacy in solid tumors has not been satisfying, mainly in the immunosuppressive network of the tumor microenvironment and paucity of appropriate target antigens. mesothelin (msln) is a tumor-associated antigen (taa) expressed in numerous types of solid tumors such as gastrointestinal, ovarian, and pancreatic tumors. owing to high expression in tumor cells and low expression in normal tissues, msln-targeted therapies like monoclonal antibodies have been previously developed. in the present study, a car t cell harboring the second-generation of a fully human anti-mslncar construct containing cd3ζ and 4-1bb signaling domains was produced and it was functionally evaluated against an msln-expressing cell line. the findings showed potent, specific proliferation, cytotoxic activity, and interleukin (il)-2, tumor necrosis factor-(tnf) α, and interferon-(ifn) γ production in an antigen-dependent manner. cytotoxic activity was shown in effector-to-target ratio from 1:1 to 20:1, but the most adequate efficacy was observed in the ratio of 10:1. non-specific activity against msln negative cell line was not observed. our data demonstrated that primary human t cells expressing fully human msln-car construct are effective against msln-expressing cell lines in vitro, suggesting this msln-car construct as a potential therapeutic tool in a clinical setting.